News Column

"Shielding of Magnetic Field as a Medical Therapy" in Patent Application Approval Process

June 26, 2014



By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventor NI, Jiu Xiang (San Francisco, CA), filed on November 29, 2013, was made available online on June 12, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents (see also Patents).

This patent application has not been assigned to a company or institution.

The following quote was obtained by the news editors from the background information supplied by the inventors: "Previous studies demonstrate that targeting microtubule dynamic instability and action in cancer cells can be an important strategy to develop new anti-cancer medicines.sup.1, 2. For instance, taxol, a potent inhibitor of human HeLa and mouse fibroblast cell replication, binds with microtubules in cancer cells, thereby blocking cell replication in G2 and M phases of cell cycle and stabilizing cytoplasmic microtubules.sup.3, 4.

"It has been known that van der Waals forces play an important role in the interactions among the proteins and the whole molecular interactions in a cell. The conventional wisdom suggests that protein folding, as well as micelle formation, is driven by the aversion for water of the nonpolar residues, known as van der Waals force.sup.5-9. Additionally, van der Waals force contributes to the formation and stability of molecular clusters.sup.10.

"Therefore, interference with or the manipulation of van der Waals forces would lead to therapeutic effects by altering dipolar molecular interactions and protein folding. While many drugs act at least in part in this manner, it would be advantageous to achieve such interference/manipulation without the use of drugs to achieve therapeutic effects. Still further, it would be advantageous to synergistically combine the non-drug induced interference/manipulation of van der Waals forces with a drug so as to achieve a greater therapeutic result."

In addition to the background information obtained for this patent application, NewsRx journalists also obtained the inventor's summary information for this patent application: "Provided herein are methods for disrupting dipolar molecular interactions in a cell so as to interfere with or manipulate molecular interactions in the cell. In one aspect, the method of this invention comprises subjecting the cell to an artificial, stable magnetic field for a period of time sufficient to result in altered dipolar interactions between molecules in the cell so as to alter the cellular physiology. In some embodiments, the period of time is at least 18 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 60 hours, or at least 72 hours.

"In one embodiment, the cell is a cancer or tumor cell undergoing rapid division, and the physiology of the cell is altered so as to reduce the rate of the division. In another embodiment, the cell is an injured cell, and the physiology of the cell is altered so as to prevent premature cell death. In some embodiments, the artificial, stable magnetic field is provided by magnetic shielding or by magnetic field stabilization, such as nuclear magnetic resonance (NMR).

"In another embodiment, the invention relates to a method for reducing undesired cell proliferation in a mammal. The method entails placing the mammal in an artificial, stable magnetic field which alters the physiology of proliferative cells, thereby reducing their rate of proliferation.

"In some embodiments, the mammal is subjected to an artificial, stable magnetic field for a period of time sufficient to alter the physiology of proliferative cells, such as at least 18 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 60 hours, or at least 72 hours. It is within the purview of one of ordinary skill to monitor the status of the mammal and the alteration of the physiology of proliferative cells such that the mammal is not subjected to an artificial, stabile magnetic field for such a long period of time that induces adverse effects to the mammal.

"In another aspect, the invention relates to a device for mammalian therapy comprising an artificial, stabilized magnetic field. The device permits the mammal to experience a localized artificial, stabilized magnetic field for a therapeutically effective time.

"In some embodiments, the device is stationary. In other embodiments, the device is portable. In one embodiment, the device permits the entire body of the mammal to experience the artificial, stabilized magnetic field. Alternatively, the device permits a portion of the mammalian body to experience the artificial, stabilized magnetic field. Preferably, a portable device is attached to or implanted in at least a portion of the mammalian body such that the portion of the mammalian body is subjected to the artificial, stabilized magnetic field.

"The therapeutically effective time can be determined by one of ordinary skill in the art by monitoring the status of the mammal and the therapeutic effects. For example, the therapeutically effective time is at least 18 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 60 hours, or at least 72 hours. Preferably, the period of time is not so long that induces adverse effects to the mammal.

"In yet another aspect, the invention relates to an assay for ascertaining the optimal condition of an artificial magnetic field therapy to maximize the therapeutic results for pathological cell growth. The method comprises the following steps:

"(a) isolating pathological cells from a mammal for in vitro culturing;

"(b) subjecting cell culture(s) of step (a) to a plurality of artificial magnetic fields wherein each of said artificial magnetic fields is maintained under different conditions from said other artificial magnetic fields;

"© comparing the growth of cell cultures in each of said artificial magnetic fields;

"(d) optionally repeating steps (a) through ©; and

"(e) determining the optimal condition of said artificial magnetic field based on the results of steps (a) through (d).

"Preferably, the condition of an artificial magnetic field therapy is optimized such that the adverse effects associated with the therapy are minimized.

"In a related aspect, the invention relates to a method for developing an in vivo personalized treatment. The method comprises:

"(a) conducting an in vitro assay for ascertaining the optimal condition of an artificial magnetic field therapy to maximize the therapeutic results for pathological cell growth, wherein the assay comprises: (i) isolating pathological cells from a mammal for in vitro culturing; (ii) subjecting cell culture(s) of step (i) to a plurality of artificial magnetic fields wherein each of said artificial magnetic fields is maintained under different conditions from said other artificial magnetic fields; (iii) comparing the growth of cell cultures in each of said artificial magnetic fields; (iv) optionally repeating steps (i) through (iii); and (v) determining the optimal condition of said artificial magnetic field based on the results of steps (i) through (iv);

"(b) correlating the optimal condition based on the in vitro assay and the condition of the in vivo treatment.

"In another related aspect, the invention relates to a method for evaluating the therapeutic effect of a non-magnetic treatment for reducing undesired cell proliferation in a mammal. The method comprises:

"(a) administering said non-magnetic treatment to said mammal;

"(b) placing said mammal in an artificial, stable magnetic field which alters the physiology of proliferative cells before, during, or after administration of said non-magnetic treatment;

"© comparing the growth of undesired cells before step (a) with the growth of undesired cells after step (b) to select the non-magnetic treatment that results in reduced growth of undesired cells after step (b).

"In some embodiments, the non-magnetic treatment is chemotherapy, radiation therapy, thermotherapy, and monoclonal antibody therapy. In other embodiments, the undesired cell proliferation is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or about 100%, following the treatment, in comparison to before the treatment.

"In yet another aspect, the invention relates to an in vitro assay for an anti-tumor agent. The method comprises:

"(a) isolating pathological cells from a mammal for in vitro culturing;

"(b) culturing cell culture(s) of step (a) in the presence of said anti-tumor agent under the condition of being subjected to an artificial, stable magnetic field and under the condition of being free of said magnetic field;

"© comparing the growth of cell cultures under each condition;

"(d) selecting the anti-tumor agent which causes more cell death under the condition of being subjected to said magnetic field than under the condition of being free of said magnetic field.

"In a further aspect, the invention relates to a combined therapy for treating a patient in need thereof. The method comprises:

"(a) administering one or more anti-tumor agents to a patient; and

"(b) subjecting the patient to an artificial, stable magnetic field which alters the physiology of proliferative cells, thereby reducing their rate of proliferation, before, after or during the treatment of the anti-tumor agent.

"In some embodiments, the anti-tumor agent is selected from the group consisting of a chemotherapy, a radiation therapy, a thermotherapy, and a monoclonal antibody therapy. In other embodiments, the undesirable side effect of or resistance to the anti-tumor agent was reduced due to reduced dosage of the anti-tumor agent and/or enhanced efficacy of the anti-tumor agent following exposure to the artificial, stable magnetic field in the combined therapy. In yet other embodiments, the patient has developed resistance to one or more anti-tumor agents.

"In a related aspect, the invention relates to a method for determining a reduced effective dose of an anti-tumor agent. The method comprises:

"(a) isolating pathological cells from a mammal for in vitro culturing;

"(b) culturing cell culture(s) of step (a) in the presence of said anti-tumor agent at various doses under the condition of being subjected to an artificial, stable magnetic field and under the condition of being free of said magnetic field;

"© comparing the growth of cell cultures treated with various doses of said anti-tumor agent under each condition;

"(d) determining a dose of said anti-tumor agent under the condition of being subjected to an artificial, stable magnetic field, which dose achieves the same reduction in cell growth but is lower than the dose under the condition of being free of said magnetic field.

"In some embodiments, the anti-tumor agent is selected from the group consisting of a chemotherapy, a radiation therapy, a thermotherapy, and a monoclonal antibody therapy.

"In another aspect, the invention relates to a method for inhibiting tumor metastasis in a mammal. The method comprises placing the mammal in an artificial, stable magnetic field for a period of time sufficient to alter the physiology of cells undergoing undesired proliferation at a secondary site that is different from the primary site of the mammal, thereby reducing the rate of undesired cell proliferation at the secondary site. Preferably, a biopsy is conducted after or during exposure of the mammal to the artificial, stable magnetic field.

"The period of time can be determined by one of ordinary skill in the art by monitoring the status of the mammal and the alteration of the physiology of the cells at the secondary site. For example, the period of time is at least 18 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 60 hours, or at least 72 hours. Preferably, the period of time is not so long that induces adverse effects to the mammal.

BRIEF DESCRIPTION OF THE DRAWINGS

"FIG. 1 demonstrates the results of surrounding magnetic field effect study and summarizes the relative NOE measurements from magnetic field shielded sample. The plot is for the solvent shell relative NOE intensity vs. temperature. In this study, the solvent was 50% DMSO-50% DMSO-d6, the toluene concentration was 0.8 M, and water concentration was 0.10 M.

"FIG. 2 demonstrates the results of the measurement of relative NOE intensities of the sample exposed to surrounding magnetic field. The plot is for the solvent shell relative NOE intensity vs. temperature. In this study, the solvent was 50% DMSO-50% DMSO-d6, the toluene concentration was 0.8 M, and water concentration was 0.10 M.

"FIG. 3 is a joined plot of DMSO 1H (T1).sub.M relaxation with surrounding magnetic field shielded (square) and without surrounding magnetic field shielded in (circle) vs. temperature.

"FIG. 4 compares the in vitro growth of non-small cell lung cancer cells in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively.

"FIG. 5 compares the in vitro growth of non-small cell lung cancer cells A549 in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively.

"FIG. 6 compares the in vitro growth of non-small cell lung cancer cells A549 in the presence of Taxol in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively.

"FIG. 7 compares the in vitro growth of non-small cell lung cancer cells A549 in the presence of various of concentrations of Taxol in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively.

"FIG. 8 compares the in vitro growth of Taxol-resistant non-small cell lung cancer cells A549-T24 in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively.

"FIG. 9 compares the in vitro growth of Taxol-resistant non-small cell lung cancer cells A549-T24 in the presence of Taxol in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively.

"FIG. 10 compares the in vitro growth of Taxol-resistant non-small cell lung cancer cells A549-T24 in the presence of various concentrations of Taxol in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively.

"FIG. 11 shows progressive cell death of non-small cell lung cancer cells A549 due to heat shock at 39.degree. C.

"FIG. 12 compares the in vitro growth of non-small cell lung cancer cells A549 post-heat shock in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively.

"FIG. 13 compares the in vitro growth of breast cancer cells MCF-7 in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively.

"FIG. 14 compares the in vitro growth of breast cancer cells MCF-7 post-heat shock in an iron shielding box (with shielding) and in a plastic box (without shielding), respectively."

URL and more information on this patent application, see: NI, Jiu Xiang. Shielding of Magnetic Field as a Medical Therapy. Filed November 29, 2013 and posted June 12, 2014. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1791&p=36&f=G&l=50&d=PG01&S1=20140605.PD.&OS=PD/20140605&RS=PD/20140605

Keywords for this news article include: Antibodies, Pharmaceuticals, Drugs, Taxol, Patents, Oncology, Immunology, Paclitaxel, Chemotherapy, Therapeutics, Blood Proteins, Lung Neoplasms, Immunoglobulins, Radiation Therapy, Cell Proliferation, Non-Small Cell Lung Cancer.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Women's Health Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters